Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease

被引：21

作者：

Foster, Norman L. ^{[1
]}

Wanga, Angela Y. ^{[1
,2
]}

Tasdizen, Tolga ^{[1
,2
]}

Fletcher, P. Thomas ^{[2
]}

Hoffman, John M. ^{[3
]}

Koeppe, Robert A. ^{[4
]}

机构：

[1] Univ Utah, Dept Neurol, Ctr Alzheimers Care Imaging & Res, Salt Lake City, UT USA

[2] Univ Utah, Sci Comp & Imaging Inst, Salt Lake City, UT USA

[3] Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA

[4] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA

来源：

ALZHEIMERS & DEMENTIA | 2008年 / 4卷 / 01期

关键词：

clinical trial design; Alzheimer's disease; brain imaging; positron emission tomography; image analysis;

D O I：

10.1016/j.jalz.2007.10.004

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Positron emission tomography (PET) with F-18-fluorodeoxyglucose (FDG-PET) thus far rarely has been used to advance the development of new treatments for Alzheimer's disease (AD). Now that FDG-PET with standard acquisition protocols for dementia is widely available, change in cerebral glucose metabolism is a feasible outcome variable for clinical drug trials. Individual analysis of FDG-PET results also might prove valuable. FDG-PET can detect metabolic changes very early in the course of AD and identify subjects for earlier treatment. FDG-PET reliably distinguishes AD from frontotemporal dementia so that only those most likely to benefit are enrolled in trials. Finally, objectively identifying phenotypic variations of AD with FDG-PET might have pathogenic and prognostic implications that can be used for personalized treatment approaches. The judicious use of FDG-PET is needed to accelerate the evaluation of promising new drugs and more rationally target treatments for dementing diseases. (c) 2008 The Alzheimer's Association. All rights reserved.

引用

页码：S29 / S36

页数：8

共 46 条

[1] Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer's disease treatment studies [J].

Alexander, GE ;

Chen, K ;

Pietrini, P ;

Rapoport, SI ;

Reiman, EM .

AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (05) :738-745

[2] Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease [J].

Anchisi, D ;

Borroni, B ;

Franceschi, M ;

Kerrouche, N ;

Kalbe, E ;

Beuthien-Beumann, B ;

Cappa, S ;

Lenz, O ;

Ludecke, S ;

Marcone, A ;

Mielke, R ;

Ortelli, P ;

Padovani, A ;

Pelati, O ;

Pupi, A ;

Scarpini, E ;

Weisenbach, S ;

Herholz, K ;

Salmon, E ;

Holthoff, V ;

Sorbi, S ;

Fazio, F ;

Perani, D .

ARCHIVES OF NEUROLOGY, 2005, 62 (11) :1728-1733

[3] Molecular imaging with Pittsburgh compound B confirmed at autopsy - A case report [J].

Bacskai, Brian J. ;

Frosch, Matthew P. ;

Freeman, Stefanie H. ;

Raymond, Scott B. ;

Augustinack, Jean C. ;

Johnson, Keith A. ;

Irizarry, Michael C. ;

Klunk, William E. ;

Mathis, Chester A. ;

DeKosky, Steven T. ;

Greenberg, Steven M. ;

Hyman, Bradley T. ;

Growdon, John H. .

ARCHIVES OF NEUROLOGY, 2007, 64 (03) :431-434

[4] THE NATURAL-HISTORY OF ALZHEIMERS-DISEASE - DESCRIPTION OF STUDY COHORT AND ACCURACY OF DIAGNOSIS [J].

BECKER, JT ;

BOLLER, F ;

LOPEZ, OL ;

SAXTON, J ;

MCGONIGLE, KL ;

MOOSSY, J ;

HANIN, I ;

WOLFSON, SK ;

DETRE, K ;

HOLLAND, A ;

GUR, D ;

LATCHAW, R ;

BRENNER, R .

ARCHIVES OF NEUROLOGY, 1994, 51 (06) :585-594

[5]

Berent S, 1999, J PSYCHIAT RES, V33, P7

[6] RELIABILITY AND VALIDITY OF NINCDS-ADRDA CRITERIA FOR ALZHEIMERS-DISEASE - THE NATIONAL-INSTITUTE-OF-MENTAL-HEALTH GENETIC INITIATIVE [J].

BLACKER, D ;

ALBERT, MS ;

BASSETT, SS ;

GO, RCP ;

HARRELL, LE ;

FOLSTEIN, MF .

ARCHIVES OF NEUROLOGY, 1994, 51 (12) :1198-1204

[7] Alzheimer disease: Improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections [J].

Burdette, JH ;

Minoshima, S ;

Borght, TV ;

Tran, DD ;

Kuhl, DE .

RADIOLOGY, 1996, 198 (03) :837-843

[8]

Caselli RJ, 2000, ADV NEUROL, V82, P35

[9] Mild cognitive impairment -: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? [J].

Chételat, G ;

Desgranges, B ;

de la Sayette, V ;

Viader, F ;

Eustache, F ;

Baron, JC .

NEUROLOGY, 2003, 60 (08) :1374-1377

[10] Research criteria for the diagnosis of Alzheimer"s disease: revising the NINCDS-ADRDA criteria [J].

Dubois, Bruno ;

Feldman, Howard H. ;

Jacova, Claudia ;

Dekosky, Steven T. ;

Barberger-Gateau, Pascale ;

Cummings, Jeffrey ;

Delocourte, Andre ;

Galasko, Douglas ;

Gauthier, Serge ;

Jicha, Gregory ;

Meguro, Kenichi ;

O'Brien, John ;

Pasquier, Florence ;

Robert, Philippe ;

Rossor, Martin ;

Solloway, Steven ;

Stern, Yaakov ;

Visser, Pieter J. ;

Scheltens, Philip .

LANCET NEUROLOGY, 2007, 6 (08) :734-746

← 1 2 3 4 5 →